Drugs / BAT1308
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT06139536 | Mar 2024 → Dec 2025 | neoplasm | Bio-Thera Solutions | Unknown | No outcome recorded |
| Phase 1 | NCT05109650 | Feb 2022 → Mar 2023 | — | Bio-Thera Solutions | Terminated | No outcome recorded |
| Phase 1 | NCT05073484 | Oct 2021 → Mar 2023 | — | Bio-Thera Solutions | Terminated | No outcome recorded |
| Phase 1 | NCT05155722 | Sep 2020 → Jul 2024 | neoplasm | Bio-Thera Solutions | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06341114 | Apr 2024 → Apr 2026 overdue | cancer | Bio-Thera Solutions | Active not recruiting | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT06321068 | Apr 2024 → May 2025 | endometrial cancer | Bio-Thera Solutions | Terminated | No outcome recorded |
| Phase 2/3 | NCT06123884 | Dec 2023 → Sep 2026 expected | cervical cancer | Bio-Thera Solutions | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BAT1308 | “The single-arm Phase II exploratory study designed to evaluate the safety and efficacy of the study drug will include 20-50 subjects to explore the safety and preliminary...” NCT06123884 ↗6“Phase II study: Safety and preliminary efficacy of BAT1308 combined with platinum-containing chemotherapy” NCT06321068 ↗ |
| Known as | BAT1308 injection | “BAT1308 injection” NCT06321068 ↗ |
| Action | Inhibit | “the anti-PD-1 IgG4 monoclonal antibody BAT1308” NCT05109650 ↗ |
| Modality | Monoclonal antibody | “combined with the anti-PD-1 IgG4 monoclonal antibody BAT1308 in subjects with advanced solid tumours” NCT05109650 ↗ |
| Route | Intravenous | “BAT1308 IV infusions” NCT05109650 ↗ |